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Abstract 
Background: Chronic conditions are expensive to treat because of the ongoing prescription cost burden. Generic drug discount 
programs (GDDPs) that offer generics at discounted price may prove beneficial to reduce pharmacy costs for the same.  
Objective: The objective of this study was to assess the extent to which GDDPs provide drug coverage for five common chronic 
conditions. 
Methods: A content analyses of preexisting information was conducted. Extent of coverage based on top 200 generic drugs 
prescribed during 2008 for the treatment of chronic conditions such as hypertension, mental disorders, arthritis, 
pulmonary/respiratory conditions, and diabetes were identified.  Commonly prescribed medications for these diseases were identified 
using published peer reviewed clinical guidelines.  List of drugs covered under a GDDP for stores, Wal-Mart, Walgreens, CVS, Kroger, 
HEB, Target, and Randalls were obtained and compared to assess drug coverage by retail dollar sales and sales volume. Descriptive 
statistics and frequency/percentage of coverage were reported using SAS 9.2. 
Results:  GDDPs covered the highest number of drugs for hypertension (21-27 across different GDDPs) and the least (3-5 across 
different GDDPs) for pulmonary/respiratory conditions. Arthritis (5-11), mental disorders (6-11) and diabetes (5-7) had similar 
coverage. When compared to the top 200 drugs by retail dollars spent during 2008, hypertension (68%-87%) and diabetes (63%-88%) 
had the highest coverage followed by respiratory conditions (30%-50%), arthritis (22%-48%), and mental disorders (21%-38%). 
Similar result was obtained when GDDP coverage was compared with the top 200 generic drugs by sales volume, where diabetes (63-
88%) and hypertension (57%-74%) had the highest coverage and mental disorders remained the lowest (23%-37%). 
Conclusion/Implications: Drug coverage in GDDPs varied by pharmacies across the five common chronic conditions evaluated which 
may limit accessibility of these programs for uninformed consumers. Drug coverage was higher for diabetes and hypertension 
compared to mental disorders, arthritis, and pulmonary/respiratory conditions. Innovative strategies such as a national GDDP 
formulary list or internet-based technological tools to help consumers identify comparative drug coverage may be useful to improve 
access to these medications.   
 
 
Introduction 
The US healthcare system is by far the most expensive when 
compared to systems in other industrialized nations.
1,2
 Some 
of the reasons attributed to this high cost include the rising 
cost of medical technology, prescription drugs, and high 
administrative costs.
3
  Further, the number of the uninsured 
who cannot afford medications increased by almost 6 million 
between 2000 and 2004 and by 3.4 million between 2004 and 
2006 making the uninsured a significant 18% of the 
population.
4,5
  Opportunities to address these issues were 
brought to light with the introduction of Generic Drug 
Discount Programs (GDDPs) by various pharmacy stores.   
 
In 2006, community pharmacies introduced GDDPs that 
would provide generics at subsidized rates to patients  
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irrespective of their insurance status.
6-8
  It was first launched 
by Wal-Mart, and currently all major community pharmacies 
offer the program. Some GDDPs may have a membership 
requirement where patients fill out a membership application 
form with their name, contact and insurance information, if 
applicable, and pay a token application fee.
6,9
 Although the 
initial intent of these programs was to increase foot traffic to 
the stores, they could be potentially be useful from patient’s 
perspective.
10,11
 Despite prescription drug expenditures 
contribute 10.7% to total health care expenditure, patients 
on average pay more out of pocket to obtain prescription 
drugs.
12,13
  
 
The situation is even worse with the uninsured population, 
who cannot afford these medications.  Polls showed that all 
Americans, both insured and uninsured, are taking advantage 
of these programs and nearly 70 million Americans have used 
GDDPs.
14
 Of these, 17% of adults and 9% of children are 
uninsured while 47% of adults and 51% of children have 
private insurance.  The poll also found that adults with heart 
diseases are more likely to use these programs.
15
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Nonetheless, no scientific literature exists on the extent of 
drug coverage across GDDPs based on disease condition. This 
information might be useful for patients having common 
chronic conditions, as they tend to use more medications for 
a long period of time.   
 
Seven out of every ten deaths in the country are caused by 
chronic diseases.
16
 Heart disease including hypertension, 
diabetes, pulmonary/respiratory conditions, mental disorders 
and arthritis are the five common chronic conditions in 
America.
16-18
 Chronic diseases would impose significant 
economic burden on the society. Promoting the use of 
generics has proven to be one of the effective strategies to 
reduce the economic burden caused by chronic diseases.
19
 
GDDPs have been hypothesized to be useful in partially 
relieving the economic burden imposed by chronic 
conditions.
20
 Pharmacists have played a leading role in 
promoting generics in part because the law permits them to 
substitute a brand medication to a generic equivalent.
21,22
  
Thus, the objective of this study was to assess the extent of 
drug coverage from GDDPs offered by community pharmacy 
chains in the Houston area for the five common chronic 
conditions.  The study also determined the proportion of 
drugs covered by these GDDPs that are among the top 200 
generic drugs prescribed during the year 2008 for the 
treatment of the identified chronic conditions. 
 
Methods 
This was a cross sectional exploratory study conducted by 
performing content analyses of existing information. The five 
common chronic conditions in America were identified using 
personal health spending, by diagnostic category and medical 
condition.
16-18
  These were hypertension, mental disorders, 
arthritis, pulmonary/respiratory conditions like asthma and 
allergic rhinitis, and diabetes.  Commonly prescribed 
medications for these diseases were then identified using 
peer reviewed clinical guidelines. The Seventh Report of the 
Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC7) 
published by the National Institute of Health was used to 
identify recommended medication for hypertension.
23
 
Recommended drugs for Alzheimer’s and associated mental 
disorders were identified using the practice guideline for the 
treatment of patients with Alzheimer’s disease and other 
dementias.
24
 Medication treatments for osteoarthritis were 
identified using the EULAR Recommendations 2003.
25
 Two 
pulmonary/respiratory conditions were studied namely 
asthma and allergic rhinitis. The Guidelines for the Diagnosis 
and Management of Asthma and the Guidelines for Clinical 
Care of Allergic Rhinitis were used to identify drugs 
recommended for treating asthma and allergic rhinitis, 
respectively.
26,27
 The Medical Guidelines for the Clinical 
Practice for the Management of Diabetes Mellitus published 
by the American Association of Clinical Endocrinologists were 
referred to for the treatment of diabetes.
28
 
 
Community pharmacies operating in Houston that offered 
GDDPs were identified from the National Association of Chain 
Drug Stores directory (NACDS), 2009 and the Yellow Pages. A 
total of seven pharmacies with 100 or more stores that 
offered GDDPs were identified and included Wal-Mart, 
Walgreens, CVS, Kroger, HEB, Target and Randalls stores. A 
GDDP list was obtained from each of these pharmacies and 
verified by tallying it with the list available on pharmacy 
website.  Data extracted from these lists were drugs or 
alternative drugs indicated for the previously identified five 
common chronic diseases and sorted according to 
indications. The drugs on the GDDP list indicated for each of 
the five chronic conditions were first compared to the clinical 
guideline recommendations and then compared to drugs that 
also appear on the 2008 list of the top 200 generic drugs by 
retail dollar sales and by sales volume dispensed.
29,30
  
Descriptive statistics was used to describe the sample 
characteristics. Extent of coverage was reported in terms of 
frequency and percentage. SAS 9.2 was used for all analyses.   
 
Results 
A total of seven community pharmacy stores with at least 100 
stores in the Houston area offered GDDPs. The characteristics 
of these pharmacies and their programs in terms of number 
of stores in the Houston area, total number of drugs covered 
in their GDDPs, and membership requirements are 
summarized in Table 1. Although, HEB has the least number 
of stores in the Houston area, it had the highest number of 
drugs in its GDDP. Whereas, CVS had highest number of 
stores in the Houston area but offered the lowest number of 
drugs in its GDDP. Three out of seven pharmacies require a 
membership to qualify for their particular GDDP. Walgreens 
offer its GDDP for the highest cost per prescription, 
specifically $9.99 for a 30-day supply and $12 for a 90-day 
supply in comparison to other stores that offer supplies for 
$4-5 and $10, respectively. 
 
Table 2 outlines the availability of generics (through 2009 and 
before) for various classes of drugs used to treat the five 
common chronic conditions.  This information would be 
useful to highlight the classes where brand only medications 
were available. In such instances, GDDPs would be of little 
help, if any.  For managing hypertension, virtually all 
diuretics, angiotensin converting enzyme inhibitors (ACEI), 
and calcium channel blockers (CCB) on the market during 
study period had no patent protection and therefore had 
generic equivalents. Others with 100% generic equivalents 
included alpha 1 blockers, alpha 2 agonist, direct vasodilators 
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as well as their combination products. Beta blockers (BBs) 
had both, brand only as well as generic equivalents. Through 
2009 all angiotensin receptor blockers (ARBs) on the market 
were still under patent and had no generic equivalents. The 
same was true for combination products containing ARBs.  All 
drugs recommended for treating anxiety and sleep disorder 
had generic equivalents on the market while all 
recommended Alzheimer’s drugs were brand only with the 
exception of Galantamine.  For schizophrenia, all typical 
antipsychotics had generic equivalents while the more 
prescribed atypical antipsychotics were brand only. In the 
treatment of osteoarthritis, all the recommended drugs for 
categories were available as generics during the study period 
except, COX inhibitors (Celecoxib), which was brand only.  
 
Insulins, thiazolidinediones and their combination, other 
antidiabetic medications such as Pramlintide (Symlin®), 
Exanatide (Byetta®), Sitagliptin (Januvia®) and their 
combination products were brand only during the study 
period.  For asthma, long acting beta agonist (LABA), 
antileukotriene agents and anti-IgE antibody were brand only 
whereas all recommending short acting beta agonist (SABA); 
corticosteroids and methylxanthines had generic equivalents. 
In the case of allergic rhinitis, second generation 
antihistamine such as Desloratadine (Calrinex®) and 
combination products containing the active ingredients were 
brand only, while all first generation antihistamine had 
generic equivalents. Antihistamine with multiple mechanisms 
of action such as Olapatadine (Pataday®, Patanol®) were 
brand only while others such as azelastine and ketotifen had 
generic equivalents.  
 
The number of recommended drugs covered in different 
GDDPs for treatment of the five common chronic conditions 
is reported in Table 3. A variation in number of recommended 
drugs covered was observed depending on the pharmacy 
chain and the chronic disease. Number of drugs covered for 
each condition was highest at CVS as compared to other 
pharmacies for all identified chronic conditions except 
osteoarthritis for which HEB carried higher number of drugs. 
Amongst the identified chronic conditions, hypertension has 
the highest number of drugs covered ranging from 21 – 27 
whereas pulmonary/respiratory disorders had the least 
coverage with only three drugs were covered at five out of 
the seven pharmacies under study.  Coverage across the five 
chronic diseases was exactly the same in programs offered by 
Randall’s and Target. Table 4 compares the coverage of 
GDDPs for the five identified chronic conditions with the list 
of the top 200 generic drugs by retail dollar sales. Diabetes 
and hypertension were well covered with up to 88% and 87% 
coverage, respectively, at CVS. On the other hand, mental 
disorders were not well covered ranging from 21% to 38% 
among different pharmacies. Coverage of osteoarthritis drugs 
varied widely ranging from 5 drugs (22%) offered by Kroger to 
11 drugs (48%) at HEB.  Table 5 compares the coverage of 
GDDPs for these five conditions with the list of the top 200 
generic drugs by sales volume. Diabetes and hypertension 
again had high extent of coverage when compared to other 
identified chronic conditions. Nonetheless, best coverage for 
hypertension dropped from 87% (compared with top 200 
generics by retail dollars) to 74% (compared with top 200 
generics by sales volume). Extent of coverage of mental 
disorders slightly increased (21%-38% by retail dollars vs. 23% 
- 37% by sales volume). 
 
Discussion 
Differences in GDDPs across pharmacies 
Consistent with previous literature, the results of the study 
indicated that the pharmacies varied in number of stores, 
number of drugs covered in their GDDPs, membership 
requirements and to a lesser extent in cost/prescription. It 
was seen that presence of pharmacy stores like CVS and 
Walgreens in greater Houston area was strong as compared 
to pharmacies within merchandise/grocery stores (Walmart, 
Target, Kroger, and HEB). However, pharmacy store programs 
covered lesser number of drugs as compared to programs 
offered by merchandise/grocery stores.  Since, GDDPs may 
make medications affordable for uninsured patients who 
forgo essential medications due to cost; they would be 
programs of choice for such individuals.  More than half (4 
pharmacies) of GDDPs examined had no membership fees 
while the rest have a small fee ranging from a onetime $5 fee 
to $35 per year for the whole family. This is important 
because GDDPs that have potential to help the poor and 
uninsured could ultimately discourage participation if high 
membership fees were imposed.
6
 It should be noted that 
both pharmacy stores (CVS and Walgreens) had membership 
fees whereas most of the merchandise/grocery store 
programs except HEB did not have any membership fee. The 
cost/prescription was somewhat uniform across most of the 
pharmacies where 30-days supply was most frequently 
available at $4 and 90-days supply at $9.99. Again, the 
pharmacy stores had a higher cost/prescription as compared 
to merchandise/grocery store programs. One reason that 
could be attributable to differences in pharmacy stores versus 
merchandise/grocery stores is that these programs could be 
helpful to attract foot traffic to the merchandise/grocery 
stores and could offset the cost associated with these 
programs.  As mentioned earlier this was the initial intent for 
developing these programs.   
 
As reported previously, variation in the list of generic drugs 
included, days of supply, enrolment requirements, and 
cost/prescription across pharmacies, may be because these 
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programs were launched by community pharmacies without 
any regulation by government.
6
 This can impact the overall 
decision making of patients creating difficulty in appropriately 
selecting a particular GDDP over another for drug availability 
at the lowest possible cost per prescription. 
 
Treatment guidelines and generic availability 
There were eight classes of single drugs recommended for 
the treatment of hypertension, out of which only one class, 
the angiotensin receptor antagonists (ARBs), had no products 
with a generic equivalent on the market during the study 
period. All recommended first line drugs for Alzheimer’s were 
brand only, so were most of the usually prescribed atypical 
antipsychotics. The implication is that patients on these 
medications will not derive any benefit from participating in 
any GDDP. While some of the newer antidepressants like 
Cymbalta® and Lexapro® were brand only, members have 
choices of similar drugs such as Venlafaxine (Effexor®) and 
Citalopram (Celexa®) that were available as generics. 
Recommended first line drugs for anxiety and sleep disorder 
were available as generics. 
 
With the exception of COX inhibitors, the recommended 
drugs for osteoarthritis were available as generics. This is 
probably the case because most of these medications are also 
prescribed for other purpose such as pain and inflammation. 
The two pulmonary/respiratory conditions examined were 
asthma and allergic rhinitis. These conditions, especially 
allergic rhinitis is more common at certain times during the 
year such as the fall season. Several of the drugs needed to 
treat these conditions are available as generics for easy 
access and affordability. In addition, most of the first and 
second-generation anti-histamines are available over-the-
counter.  Biguanides and sulfonylurea’s, two commonly 
prescribed first line drugs for type 2 diabetes are available as 
generics. This is important because more individual have 
type-2 diabetes. Several other classes of diabetic drugs also 
had generic equivalent for patients to choose. 
 
 Hypertension had the highest number of drugs available in 
GDDPs among all the chronic diseases examined. This implies 
that GDDPs could be useful to a huge number of patients 
because hypertension is one of the most common chronic 
diseases affecting an estimated 26% of the population.
31
 
Mental and pulmonary/respiratory disorders were not well 
covered. The number of drugs available for diabetes was also 
low. Biguanides and sulfonylureas were the only class of 
drugs for diabetes that were available by GDDPs. Although 
CVS and Walgreens had least total number of drugs in their 
GDDPs the number of medications available for identified 
chronic conditions was high as compared to GDDPs offered 
by most of the other pharmacies.  This indicates that just 
because a store advertises that it has more number of drugs 
on the list does not mean the program may have the highest 
benefit for all consumers.  
 
Extent of coverage in GDDPs as compared to top 200 generics 
Out of all the diabetes drugs that appeared in top 200 generic 
drugs by retail dollar sales (2008), 63% - 87% were covered by 
GDDPs offered across different pharmacies. Similarly, 
hypertension also had a high coverage (68% - 78%). This 
indicates that the pharmacy chains are responding to 
members need for affordability of drugs for these two chronic 
diseases. On the other hand extent of coverage for arthritis, 
as well as mental and pulmonary disorders is well below 50% 
indicating the need for better coverage in these areas. 
GDDP coverage, when compared to the 2008 top 200 generic 
drugs by sales volume dispensed, was between 63% - 88% of 
drugs prescribed for diabetes and 57% - 74% of drugs for 
hypertension. Better coverage for hypertension and diabetes 
in comparison to top 200 generics both by retail dollars and 
sales volume indicate the availability of choice for members 
with these chronic conditions. Coverage of arthritis, mental 
and pulmonary/respiratory conditions were again below 50%.  
The lack of coverage for some of these common chronic 
diseases along with the variability of coverage between 
GDDPs may limit access for patients that are not well 
informed.  There is a need to address ways in which greater 
coverage can be encouraged.  This could be accomplished by 
developing a national list for GDDPs by national organizations 
or self-regulated by the industry.  
 
Results of this study should be viewed in light of the following 
limitations. Reliance on clinical guidelines when prescribing 
patterns might not be in accordance with the same may 
affect our results. Pharmacies may be constantly reviewing 
their GDDP and the current lists may change in the future to 
reflect demand. Although pharmacies selected in this study 
are present across the nation, they maintain strengths that 
differ by geographical location for strategic reasons and a 
pharmacy with a large presence in one location may be small 
or absent in other locations. For these reasons, the results of 
this study would be reasonable but not completely 
generalizable.   
 
Problems associated with access and affordability of drugs is 
ongoing, increase in cost of medication and general health 
care costs continue to hinder health care delivery. GDDPs 
could be one way of slowing down cost and increasing access. 
Thus, future studies looking at factors that limit access to use 
of GDDPs, impact of GDDPs on cost of medications, and 
understanding the criteria used to include drugs on GDDPs 
might be useful. As mentioned earlier, these programs are 
open to both insured and uninsured consumers and 
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reportedly substantial proportion of insured consumers use 
these programs.
14
 When an insured consumer fills a 
prescription using GDDP the claim for that particular 
prescription is not reported to the insurance company. Future 
studies are required that evaluate practice characteristics of 
insured consumers utilizing these programs and resulting 
impact of such patient behavior on continuum of care. 
 
Conclusion 
GDDPs varied by pharmacies across the chronic conditions 
evaluated, which can limit accessibility of these programs for 
consumers and lead to discrimination based on where a 
consumer shops. The number of drugs covered varied across 
both, the chronic conditions as well as GDDPs offered.  This 
can lead to ignorance and require additional efforts on the 
patient’s end to receive medications at an optimum price. 
Guidelines should be available to help pharmacy formulate 
and improve their GDDPs in order to improve and bring 
consistency in their coverage. 
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Table 1: Characteristics of GDDPs
a
 offered by community pharmacies across the Houston area 
 
a 
Generic Drug Discount Programs 
b
 Individual membership per year 
c 
Family membership per year  
d 
One time membership fee for life for a family of 4 
e 
Store did not offer the program for the specific days supply 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Walgreens Kroger CVS Randalls Walmart Target HEB 
 
Number of stores in Houston 
 
382 291 256 199 197 151 114 
 
Number of drugs in GDDPs
 a 
 
292 383 246 322 339 384 507 
 
Membership charge 
 
$20
b
/$35
c
 None $10
b
 None None None $5
d
 
 
Cost/prescription – 30 days supply 
 
$9.99 $4 N/A
e
 $4 $4 $4 $5 
 
Cost/prescription – 90 days supply 
 
$12 $10 $9.99 N/A
e
 $10 $10 $9.99 
Student Project PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                         2012, Vol. 3, No. 2, Article 81                         INNOVATIONS in pharmacy   8 
 
Table 2: Availability of generic equivalents for the five common chronic conditions 
            Drug Availability
a
 
Class/Disease Generic Brand Only 
Hypertension 
Diuretics Yes No 
Beta-Blockers Yes Yes 
Angiotensin Converting enzyme inhibitors (ACEIs) Yes No 
Angiotensin II Receptor blockers (ARBs) No Yes 
Calcium Channel Blockers (CCBs) Yes No 
Alpha-1-blockers Yes  No 
Alpha-2-agonists Yes No 
Direct Vasodilators Yes No 
ACEIs + CCBs No Yes 
Diuretic + Diuretic Yes No 
ACEIs + Diuretic Yes No 
ARBs + Diuretic No Yes 
BBs + Diuretic Yes No 
Centrally acting drug + Diuretic Yes  No 
Mental Disorders 
Depression Yes Yes 
Schizophrenia Yes (Typical) No (Atypical) 
Alzheimer Yes Yes 
Anxiety Yes No 
Sleep disorder Yes No 
Osteoarthritis 
Acetaminophen Yes No 
NSAIDs Yes No 
Coxibs No Yes 
Corticosteroids Yes No 
Opiod receptor agonists Yes No 
Diabetes 
Insulin No Yes 
Sulfonylureas Yes No 
Biguanides Yes No 
Thiazolidinediones No Yes 
Glinides Yes Yes 
Alpha-glucosidase inhibitors Yes Yes 
Combination drugs Yes Yes 
New Drugs  No Yes 
Pulmonary/Respiratory Conditions – Asthma 
Short acting beta agonist (SABA) Yes No 
Long acting beta agonist (LABA) No Yes 
Anticholinergics Yes Yes 
Antileukotriene agents No  Yes 
Mast cell stabilizers Yes  Yes 
Methylxanthines Yes No 
Anti-IgE antibody No Yes 
Corticosteroids No Yes 
Pulmonary/Respiratory Conditions – Allergic Rhinitis 
Corticosteroids Yes No 
1
st
 generation Oral antihistamines No Yes 
2
nd
 generation Oral antihistamines Yes Yes 
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Table 2: (continued)   
Antileukotriene agents No Yes 
Mast cell stabilizers Yes Yes 
Combination products Yes Yes 
Other antihistamines Yes Yes 
a 
Availability of drugs in each of the two categories, Generic or Brand only. For example, diuretics had all brand name  
drugs available as generics. Beta-Blockers had some brand name drugs available as generic equivalents and also had  
some brand only medications, while ARBs had only brand name drugs available and no generic equivalent medications.  
 
 
 
 
 
 
 
 
 
Table 3: Number of drugs available in GDDPs
a
 to treat the five common chronic conditions 
 
                                              Number (N) of drugs 
Chronic Condition Walgreens Krogers CVS Randalls Walmart Target HEB 
 
Hypertension 
 
 
24 
 
21 
 
27 
 
21 
 
21 
 
21 
 
26 
 
Mental Disorders 
 
 
7 
 
6 
 
11 
 
6 
 
6 
 
6 
 
6 
 
Osteoarthritis 
 
 
9 
 
5 
 
10 
 
6 
 
7 
 
6 
 
11 
 
 
Pulmonary/Respiratory 
Conditions 
 
4 
 
3 
 
5 
 
3 
 
3 
 
3 
 
3 
 
Diabetes 
 
 
6 
 
5 
 
7 
 
5 
 
5 
 
5 
 
5 
     a 
Generic Drug Discount Programs 
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Table 4: Comparison of GDDPs
a
 list to the 2008 top 200 generic drugs by retail dollar sales for pharmacies by chronic conditions 
 
 Number (N) and GDDPs Coverage (%) of Top 200 Generic Drugs 
Chronic Condition Top 200 
Drugs 
Walgreens Kroger    CVS Randalls Walmart Target HEB 
 
Hypertension  
 
 
31 
 
24(77%) 
 
21(68%) 
 
27(87%) 
 
21(68%) 
 
21(68%) 
 
21(68%) 
 
26(84%) 
 
Mental Disorders 
 
 
29 
 
7(24%) 
 
6(21%) 
 
11(38%) 
 
6(21%) 
 
6(21%) 
 
6(21%) 
 
6(21%) 
 
Osteoarthritis 
 
 
23 
 
9(39%) 
 
5(22%) 
 
10(44%) 
 
6(26%) 
 
7(30%) 
 
6(26%) 
 
11(48%) 
 
Pulmonary/Respiratory 
Conditions 
 
10 
 
4(40%) 
 
3(30%) 
 
5(50%) 
 
3(30%) 
 
3(30%) 
 
3(30%) 
 
3(30%) 
 
Diabetes 
 
 
8 
 
6(75%) 
 
5(63%) 
 
7(88%) 
 
5(63%) 
 
5(63%) 
 
5(63%) 
 
5(63%) 
 
a 
Generic Drug Discount Programs 
 
 
 
Table 5: Comparison of GDDPs
a
 list to the 2008 top 200 generic drugs by sales volume for pharmacies by chronic conditions 
 
Number (N) and GDDPs Coverage (%) of Top 200 Generic Drugs 
Chronic Condition Top 200 
Drugs 
Walgreen
s 
Kroger CVS Randalls Walmart Target HEB 
 
Hypertension  
 
 
35 
 
23(66%) 
 
21(60%) 
 
26(74%) 
 
20(57%) 
 
21(60%) 
 
21(60%) 
 
25(71%) 
 
 
Mental Disorders 
 
 
35 
 
9(26%) 
 
9(26%) 
 
13(37%) 
 
8(23%) 
 
10(29%) 
 
9(29%) 
 
9(26%) 
 
Osteoarthritis 
 
 
25 
 
10(40%) 
 
7(28%) 
 
10(40%) 
 
8(32%) 
 
9(36%) 
 
8(32%) 
 
11(44%) 
 
Pulmonary/Respiratory 
Conditions 
 
11 
 
5(46%) 
 
4(36%) 
 
4(36%) 
 
2(18%) 
 
4(36%) 
 
4(36%) 
 
4(36%) 
 
Diabetes 
 
 
8 
 
6(75%) 
 
5(63%) 
 
7(88%) 
 
5(63%) 
 
5(63%) 
 
5(63%) 
 
5(63%) 
a 
Generic Drug Discount Programs 
 
 
 
